Article Type
Review
Published
Lenacapavir (LEN), a first in-class capsid inhibitor, is approved as a twice-yearly subcutaneous injection for HIV prevention and represents a major advance beyond daily oral and bi-monthly injectable long-acting pre-exposure prophylaxis regimens.